Aclarion's Nociscan AI Technology Gains Traction in Chronic Low Back Pain Diagnosis

Aclarion, Inc., a healthcare technology company specializing in chronic low back pain diagnosis, has reported significant progress in the development and adoption of its Nociscan AI technology. The company's recent achievements suggest a growing acceptance of Nociscan as a potential standard of care in identifying the source of chronic low back pain, a condition that costs Americans an estimated $134 billion annually.

Nociscan, which uses biomarkers and proprietary AI algorithms to help physicians locate the source of chronic low back pain, has reached several key milestones. Notably, three of the four largest private insurance payers in the UK have agreed to cover the technology, marking a crucial step towards widespread adoption. This development in the UK market serves as a model for Aclarion's expansion strategy in the United States.

The company has also formed partnerships with ten prominent Key Opinion Leader (KOL) surgeons to assist in gaining traction and reimbursement throughout the United States. These partnerships are critical for advocating the technology's efficacy to insurance companies and benefits management entities, potentially leading to increased coverage decisions.

Aclarion's strategy involves collaborating with KOL physicians who recognize Nociscan's value in their practice. This approach has proven successful in the UK, where physicians' positive evaluations led to a commercial agreement with The London Clinic and subsequent insurance coverage decisions. The company is now replicating this model in the United States, leveraging its KOL network to drive adoption and secure payer coverage.

In addition to its KOL strategy, Aclarion has entered into a strategic partnership with ATEC, a major spine implant company. This collaboration aims to expand Aclarion's KOL advocacy to additional surgeons and integrate Nociscan technology with ATEC's Alpha-Informatics platform, potentially improving spine patient care outcomes.

The company is also making inroads into the personal injury and workers' compensation market, where accurate diagnosis is particularly crucial. By partnering with orthopedic spine surgeon Dr. Justin Kubeck, Aclarion is working to educate attorneys and judges on the benefits of Nociscan in these high-stakes cases.

Clinical evidence supporting Nociscan's efficacy continues to accumulate. The company has published peer-reviewed articles demonstrating improved and durable clinical outcomes when Nociscan results guide surgical treatment. Additionally, an economic analysis commissioned by Aclarion suggests that widespread use of Nociscan could save the US healthcare system nearly half a billion dollars annually.

Aclarion is currently conducting CLARITY, a prospective, randomized, multi-center trial comparing outcomes of patients undergoing surgery for chronic discogenic back pain with and without Nociscan in the decision-making process. The company anticipates that positive results from this study could lead to coverage decisions from major insurance providers and endorsements from spine societies.

With 23 issued US patents, 17 issued international patents, and 12 pending patent applications, Aclarion has established a strong intellectual property position in the MR spectroscopy space. The company continues to expand its IP portfolio, recently adding patents related to AI analysis techniques and the identification of bacterial biomarkers associated with pain.

As Aclarion progresses towards its goal of establishing Nociscan as a standard of care, investors can expect continued developments in peer-reviewed evidence publications, commercial agreements, and payer coverage decisions. The company's advancements in AI-driven pain diagnosis technology could potentially transform the approach to chronic low back pain treatment, offering hope for more accurate diagnoses and improved patient outcomes in this widespread and costly health issue.